Nasal Polyps
Chronic rhinosinusitis with nasal polyps improves with tezepelumab
SAN DIEGO — Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to an abstract presented here.
Risk factors impact denials, wait times, discontinuations in biologic treatment for asthma
SAN DIEGO — Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, as well as with discontinuations, according to a series of posters presented here.
Top in allergy/asthma: Alternative to epinephrine injections; food allergy testing in kids
A study involving an oral allergen challenge revealed promising results for a sublingual epinephrine strip, a delivery method that is being evaluated as an alternative to epinephrine autoinjectors.
Biologic use low among patients with chronic rhinosinusitis with nasal polyps
BOSTON — Patients with chronic rhinosinusitis with nasal polyps showed low biologics use and high discontinuation rates, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
FDA approves dupilumab for adolescents with chronic rhinosinusitis with nasal polyps
Regeneron Pharmaceuticals Inc. and Sanofi announced the FDA approval of dupilumab for adolescents aged 12 to 17 years with chronic rhinosinusitis with nasal polyps.
Conference targets allergy, asthma topics for advanced practitioners
The prevalence of allergic diseases continues to grow, and so does the need for clinical training — especially for physician assistants, nurse practitioners and other allied health care professionals.
Mepolizumab safety profile comparable with placebo across 32 studies, multiple indications
SAN DIEGO — Rates of serious adverse events for patients on mepolizumab were comparable with those using placebo across 7,429 patient-years of exposure, according to a presentation at the American Thoracic Society International Conference.
Top in allergy/asthma: Allergen immunotherapy may prevent asthma; EHR prompts beneficial
Patients who received subcutaneous allergen immunotherapy for house dust mite had a reduced probability of asthma onset and development of asthma from allergic rhinitis over time, according to a recent study.
FDA grants priority review to dupilumab for adolescents with CRSwNP
The FDA has accepted for priority review the supplemental biologics license application of dupilumab for adolescents with chronic rhinosinusitis with nasal polyps, Regeneron Pharmaceuticals Inc. and Sanofi announced in a press release.
FDA OKs fluticasone propionate nasal spray for chronic rhinosinusitis without nasal polyps
The FDA has approved fluticasone propionate nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients aged 18 years and older, according to an Optinose press release.